1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Peripheral Vasodilator Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Prevalence & Incidence Rate globally with key countries
5.2. Regulatory Scenario by Region/globally
5.3. COVID-19 Pandemics Impact on Industry
6. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Calcium Channel Blockers
6.3.2. Direct-acting Vasodilators
6.3.3. Alpha-adrenergic Blockers
6.3.4. Potassium Channel Activators
6.3.5. Nitrates
6.3.6. Others
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Peripheral Vasodilator Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Type, 2017–2031
9.2.1. Calcium Channel Blockers
9.2.2. Direct-acting Vasodilators
9.2.3. Alpha-adrenergic Blockers
9.2.4. Potassium Channel Activators
9.2.5. Nitrates
9.2.6. Others
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Peripheral Vasodilator Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2017–2031
10.2.1. Calcium Channel Blockers
10.2.2. Direct-acting Vasodilators
10.2.3. Alpha-adrenergic Blockers
10.2.4. Potassium Channel Activators
10.2.5. Nitrates
10.2.6. Others
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Peripheral Vasodilator Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017–2031
11.2.1. Calcium Channel Blockers
11.2.2. Direct-acting Vasodilators
11.2.3. Alpha-adrenergic Blockers
11.2.4. Potassium Channel Activators
11.2.5. Nitrates
11.2.6. Others
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Peripheral Vasodilator Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. Calcium Channel Blockers
12.2.2. Direct-acting Vasodilators
12.2.3. Alpha-adrenergic Blockers
12.2.4. Potassium Channel Activators
12.2.5. Nitrates
12.2.6. Others
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Peripheral Vasodilator Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017–2031
13.2.1. Calcium Channel Blockers
13.2.2. Direct-acting Vasodilators
13.2.3. Alpha-adrenergic Blockers
13.2.4. Potassium Channel Activators
13.2.5. Nitrates
13.2.6. Others
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2022
14.3. Company Profiles
14.3.1. Pfizer, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Novartis AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. GSK plc
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. AstraZeneca
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Merck & Co., Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Sanofi
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Bayer AG
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Abbott Laboratories
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Bristol-Myers Squibb Company
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Boehringer Ingelheim International GmbH
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Teva Pharmaceutical Industries Ltd.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. Financial Overview
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. Viatris, Inc.
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Product Portfolio
14.3.12.3. Financial Overview
14.3.12.4. SWOT Analysis
14.3.12.5. Strategic Overview
14.3.13. Sun Pharmaceutical Industries Ltd.
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Product Portfolio
14.3.13.3. Financial Overview
14.3.13.4. SWOT Analysis
14.3.13.5. Strategic Overview
14.3.14. Lupin
14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.14.2. Product Portfolio
14.3.14.3. Financial Overview
14.3.14.4. SWOT Analysis
14.3.14.5. Strategic Overview
世界の末梢血管拡張薬市場2023-2031：薬剤別（カルシウムチャネル拮抗薬、直接作用型血管拡張薬、αアドレナリン拮抗薬、カリウムチャネル活性化剤、硝酸塩、その他） |
| 【英語タイトル】Peripheral Vasodilator Drugs Market (Drug Type: Calcium Channel Blockers, Direct-acting Vasodilators, Alpha-adrenergic Blockers, Potassium Channel Activators, Nitrates, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 | |
 | ・商品コード：TMR23MA064 ・発行会社（調査会社）：Transparency Market Research ・発行日：2023年3月13日 ・ページ数：130 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後24時間以内） ・調査対象地域：北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ ・産業分野：医薬品 |
| Single User（1名様閲覧） | USD5,795 ⇒換算￥869,250 | 見積依頼/購入/質問フォーム |
| Multi User（5名様閲覧） | USD8,795 ⇒換算￥1,319,250 | 見積依頼/購入/質問フォーム |
| Corporate License（法人閲覧） | USD11,795 ⇒換算￥1,769,250 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| Transparency Market Research社の当調査資料では、世界の末梢血管拡張薬市場規模が、2023年の60億ドルから2031年に90億ドルとなり、予測期間中に年平均5.3%で成長すると予想しています。本書は、末梢血管拡張薬の世界市場について調べ、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬剤別（カルシウムチャネル拮抗薬、直接作用型血管拡張薬、αアドレナリン拮抗薬、カリウムチャネル活性化剤、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目をまとめています。なお、当市場の主要企業として、Pfizer, Inc.、Novartis AG、GSK plc、AstraZeneca、Merck & Co., Inc.、Sanofi、Bayer AG、Abbott Laboratories、Bristol-Myers Squibb Company、Boehringer Ingelheim International GmbH、Teva Pharmaceutical Industries Ltd.、Viatris, Inc.、Sun Pharmaceutical Industries Ltd.、Lupinなどが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の末梢血管拡張薬市場規模：薬剤別 - カルシウムチャネル拮抗薬の市場規模 - 直接作用型血管拡張薬の市場規模 - αアドレナリン拮抗薬の市場規模 - カリウムチャネル活性化剤の市場規模 - その他薬剤の市場規模 ・世界の末梢血管拡張薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界の末梢血管拡張薬市場規模：地域別 - 北米の末梢血管拡張薬市場規模 - ヨーロッパの末梢血管拡張薬市場規模 - アジア太平洋の末梢血管拡張薬市場規模 - 中南米の末梢血管拡張薬市場規模 - 中東・アフリカの末梢血管拡張薬市場規模 ・競争状況 |
Peripheral Vasodilator Drugs Market – Scope of Report
TMR’s report on the global peripheral vasodilator drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global peripheral vasodilator drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peripheral vasodilator drugs market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the peripheral vasodilator drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peripheral vasodilator drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peripheral vasodilator drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peripheral vasodilator drugs market.
The report delves into the competitive landscape of the global peripheral vasodilator drugs market. Key players operating in the global peripheral vasodilator drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peripheral vasodilator drugs market profiled in this report.
Key Questions Answered in Global Peripheral Vasodilator Drugs Market Report
• What is the sales/revenue generated by peripheral vasodilator drugs across all regions during the forecast period?
• What are the opportunities in the global peripheral vasodilator drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Peripheral Vasodilator Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global peripheral vasodilator drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global peripheral vasodilator drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peripheral vasodilator drugs market.
❖ レポートの目次 ❖
| ★調査レポート[世界の末梢血管拡張薬市場2023-2031：薬剤別（カルシウムチャネル拮抗薬、直接作用型血管拡張薬、αアドレナリン拮抗薬、カリウムチャネル活性化剤、硝酸塩、その他）] (コード：TMR23MA064)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の末梢血管拡張薬市場2023-2031：薬剤別（カルシウムチャネル拮抗薬、直接作用型血管拡張薬、αアドレナリン拮抗薬、カリウムチャネル活性化剤、硝酸塩、その他）]についてメールでお問い合わせ |
